RxDoctor Payments Data

Katherine McDonell, MD

Neurology · Nashville, TNNPI 1275844508

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,760 of the $11,013 with a category attached, or 88.6%. Teva Pharmaceuticals USA, Inc. accounts for 94.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $9,924 and has fallen 98.0% since, to $199 in 2025.

$11,013in general payments, 2019–2025

Across 46 payments — averaging $239.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$10K
  • Neurocrine Biosciences, Inc.$510
  • Eisai Inc.$90
$850,639in research payments, 2019–2025

Across 60 payments — averaging $14,177 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$835K
  • Lundbeck LLC$16K

What the payments were for

  • Consulting fees$9,76089%
  • Food & beverage$1,25311%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,013 in reported general payments places this provider in the 65th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$7,972
Medicare patients
42
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine89$1,025,629
IngrezzaValbenazine Tosylate68$545,531
Austedo XrDeutetrabenazine38$223,116
Tetrabenazine13$2,395
Memantine Hcl35$768
Mirtazapine25$557
Sertraline Hcl51$550
Carbidopa-LevodopaCarbidopa/Levodopa20$422
Donepezil Hcl31$404
Gabapentin25$328
Quetiapine Fumarate26$322
Risperidone16$155
Venlafaxine Hcl ErVenlafaxine Hcl15$142
Aripiprazole18$128
Clonazepam46$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$10,414$1,248,744127 claims
Neurocrine Biosciences, Inc.Ingrezza$510$545,53168 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 361 neurology providers in Tennessee.

Other neurology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →